Fig. 1 · Structure

Documents & Downloads

LCL-161

Cat. No. A11928 CAS 1005342-46-0

Antagonist of IAPs inhibitor

LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity.

In Stock

Publications for LCL-161

10 publications citing this product

  1. Da-Hye Jeong, .et al. , Adv Sci (Weinh), 2025, Apr;12(13):e2412393 PMID: 39921454
  2. Oliver H, .et al. , J Med Chem, 2023, 66, 16, 11216-11236 PMID: 37535857
  3. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  4. Han-Hee Park, .et al. , Mol Cancer, 2021, Aug 21;20(1):107 PMID: 34419074
  5. Se-Yeon Park, .et al. , Cell Death & Disease, 2020, 11:744 PMID: 32917855
  6. J Chen, .et al. , JBC, 2019, June PMID: 31217278
  7. Choi SW, .et al. , Mol Cell, 2018, Jun 7;70(5):920-935.e7 PMID: 29883609
  8. Han-Hee Park, .et al. , Exp Mol Med, 2018, Sep; 50(9): 125 PMID: 30237400
  9. Gi-Bang Koo, .et al. , Cell Res, 2015, Jun; 25(6): 707-725 PMID: 25952668
  10. Kim SK, .et al. , J Invest Dermatol, 2015, Aug;135(8):2021-2030 PMID: 25748555

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

LCL161 is a SMAC mimetic used to perturb IAP signaling. In OSCC cells, 1 μM LCL161 for 24 h reduced cIAP1 protein in both sensitive and resistant models, while cIAP2 remained low and largely unchanged. Target-protein loss alone did not predict cell killing. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
cIAP
XIAP

Cellular Effect

Cell Line Activity Value Description Reference
MDA-MB-231 IC50 7.8 nM Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay [PMID: 30091600]
MDA-MB-231 EC50 7.8 nM Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 72 hrs by alamar blue assay [PMID: 28492317]
SK-OV-3 EC50 1 nM Induction of apoptosis in human SKOV3 cells assessed caspase-3 activation after 48 hrs by IncuCyte S3 live-cell analysis [PMID: 31095386]
SK-OV-3 EC50 3 nM Induction of apoptosis in human SKOV3 cells assessed caspase-3 activation after 24 hrs by IncuCyte S3 live-cell analysis [PMID: 31095386]

LCL-161 Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of LCL-161 from 2 published references.

LCL-161 In Vitro Studies

OSCC responses varied by cell line. After 24 h at 0.5 or 1 μM, HSC-3 and HN6 were sensitive in a CCK-8 assay, whereas seven other OSCC lines were comparatively resistant. Annexin V/PI analysis supported increased apoptosis in HSC-3 with little response in CAL-33. These concentrations are treatment exposures, not IC50 values. [1]

OSCC cellular response and cIAP1 loss

Cell-based study · Human OSCC panel: HSC-3, HN6, HSC-2, CAL-33, SCC-172, SCC-131, SCC-9, SCC-4 and CAL-27; cIAP response blots in HSC-3, HN6, CAL-33 and SCC-9. [1]

A single-agent response profile combined viability, apoptosis and cIAP immunoblot assays. HSC-3 and HN6 were sensitive, whereas the other seven lines were comparatively resistant. cIAP1 loss occurred in both response classes and cIAP2 remained low and largely unchanged in the tested blots; cIAP1 loss alone therefore did not predict cell killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability relative to untreated controlCCK-8 HSC-3 and HN6 were sensitive; HSC-2, CAL-33, SCC-172, SCC-131, SCC-9, SCC-4 and CAL-27 were comparatively resistant at 0.5 or 1 μM for 24 h. No exact viability percentages extracted.[1]
Annexin V/PI apoptosis profileFlow cytometry LCL161 increased early and late apoptotic fractions in HSC-3; CAL-33 showed little response after 24 h.[1]
cIAP1 and cIAP2 protein abundanceWestern blot 1 μM, 24 h: cIAP1 decreased in HSC-3, HN6, CAL-33 and SCC-9; cIAP2 remained low and unaltered.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 or 1 μM for viability/apoptosis; 1 μM for immunoblotting.
Exposure duration
24 h
Method
Single-agent cell exposure; untreated controls. No exogenous TNF in these selected assays.
Reported limits
Cellular LCL161 solvent/vehicle is not specified in the selected methods. Exact panel-specific n is not specified in the captions.
Methods and source locations

Compound reported in the paper: LCL161; Compound label in the paper: LCL161

Results describe the paper’s LCL161 material; supplier and formulation do not establish equivalence of a current Adooq lot.

Figs 3A–H and 4A–C; relevant Results; Methods, Reagents and antibodies, Cell culture, Cell viability assay, Flow cytometry, Western blot, Statistical analysis

Cell viability relative to untreated control: CCK-8 absorbance at 450 nm, control- and blank-normalized; Fig. 3A/B show mean ± SD, ANOVA. Statistical methods state validation by three or more independent experiments; panel-specific replicate number is not given in the caption. — Fig. 3A/B and caption; Results, OSCC tumor cells exhibit differential sensitivity; Methods, Cell viability assay and Statistical analysis

Annexin V/PI apoptosis profile: Annexin V-FITC/PI; representative plots and summary bars for 0, 0.5 and 1 μM. No exact population percentages transcribed from representative plots. — Fig. 3C–F and caption; Methods, Flow cytometry

cIAP1 and cIAP2 protein abundance: LCL161-treated versus untreated cells; GAPDH loading control. Qualitative interpretation of viewed blots, not a biochemical affinity or IC50 assay. — Fig. 4B/C and caption; Results, cIAP1 is degraded upon SM treatment; Methods, Western blot

LCL-161 In Vivo Studies

In female BALB/c nude mice, intraperitoneal LCL161 at 20 mg/kg every two days for five administrations inhibited HSC-3 xenograft growth but did not inhibit CAL-33 growth. Tumor cIAP1 staining decreased in both models. Body weight did not differ detectably under this schedule; it does not establish systemic safety. [1]

In transplantable Vk*MYC myeloma, oral LCL161 at 100 mg/kg on days 1, 4, 8 and 11 reduced day-14 M-spike burden in Vk12598 but was inactive as a single agent in Vk12653. These model-specific responses do not establish uniform activity across myeloma. [2]

Contrasting LCL161 responses in HSC-3 and CAL-33 xenografts

Animal study · Subcutaneous HSC-3 and CAL-33 human OSCC xenografts in four-week-old female BALB/c nude mice. [1]

LCL161 reduced HSC-3 tumor growth but failed to reduce CAL-33 growth. Both models showed reduced cIAP1 immunostaining without a significant cIAP2 change. Body weights did not differ detectably under this schedule; this endpoint does not establish systemic safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume response by xenograft modelTumor volume HSC-3: lower tumor growth, P < 0.001; CAL-33: no significant reduction, P = 0.442. Final tumor-volume panels show vehicle/LCL161 n = 7/9 for HSC-3 and 10/10 for CAL-33.[1]
Tumor cIAP1 and cIAP2 IHC scoresIHC cIAP1 lower: HSC-3 P = 0.0003 (vehicle n = 7, LCL161 n = 9), CAL-33 P = 0.0146 (n = 10 each). cIAP2: HSC-3 P = 0.9574, CAL-33 P = 0.1667.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every two days
Treatment course
Five administrations; terminal assessment day 20 after inoculation.
Vehicle
30% 0.1 N hydrochloric acid + 70% 0.1 N anhydrous sodium acetate solution (reported vehicle).
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
HSC-3: LCL161 versus vehicle
20 mg/kg
Matched vehicle group.Tumor growth blunted (P < 0.001); cIAP1 IHC decreased; cIAP2 and body-weight responses were not significant.[1]
CAL-33: LCL161 versus vehicle
20 mg/kg
Matched vehicle group.No reduction in tumor growth (P = 0.442), despite lower cIAP1 IHC; cIAP2 and body-weight responses were not significant.[1]
HSC-3: LCL161 versus vehicle
Model: HSC-3 xenografts in female BALB/c nude mice
Reported limits: Final plotted n = 7 vehicle and 9 LCL161; reduction from planned group size unexplained.
CAL-33: LCL161 versus vehicle
Model: CAL-33 xenografts in female BALB/c nude mice
Reported limits: Final plotted n = 10 per group.
Methods and source locations

Compound reported in the paper: LCL161; Compound label in the paper: SM (LCL161)

Results describe the paper’s LCL161 material; supplier and formulation do not establish equivalence of a current Adooq lot.

Figs 3I–O and 4D–G; relevant Results; Methods, Mice, Mouse subcutaneous xenograft OSCC model, Histological preparation and IHC, Statistical analysis

Tumor volume response by xenograft model: Caliper volumes (length × width × width / 2); Fig. 3L/N plot days 10 and 20; mean ± SD; t-test. No exact volumes digitized. — Fig. 3J–O, especially L/N; caption; Methods, Mouse subcutaneous xenograft OSCC model

Tumor cIAP1 and cIAP2 IHC scores: Fig. 4D–G mean ± SD, Student’s t-test; intensity × positive-percentage scoring. Values are printed in the viewed figure; exact IHC score means not extracted. — Fig. 4D–G and caption; Results, cIAP1 is degraded upon SM treatment; Methods, Histological preparation and IHC

HSC-3: LCL161 versus vehicle · Fig. 3I/J/L/M; Fig. 4D/F; Methods, Mouse subcutaneous xenograft OSCC model

CAL-33: LCL161 versus vehicle · Fig. 3I/K/N/O; Fig. 4E/G; Methods, Mouse subcutaneous xenograft OSCC model

Model-dependent response in transplantable Vk*MYC myeloma

Animal study · Vk12598 and Vk12653 transplantable myeloma in congenic C57BL/6J mice, 8–12 weeks old, both sexes. [2]

Single-agent LCL161 reduced M-spike levels in Vk12598 but was inactive in the multidrug-refractory Vk12653 model. This response contrast limits generalization of anti-myeloma activity. Combination regimens and the separate de novo transgenic experiment are not represented as single-agent results.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum monoclonal M-spike responsePercentage of day-0 M-spike Vk12598: active; Vk12653: inactive as single agent at day 14. Response cutoff: >50% M-spike reduction; regimen activity cutoff: >20% response rate, as defined in Fig. 1 caption.[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Days 1, 4, 8 and 11
Treatment course
Four administrations over two weeks; M-spike on day 14.
Vehicle
30% HCl 0.1 N + 70% sodium acetate 100 mM, pH 4.5; LCL161 stock 10 mg/mL as reported.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vk12598 single agent
100 mg/kg
Vehicle-treated Vk12598 tumor-bearing mice in Fig. 1b.Reduced M-spike burden; classified active in the reported model.[2]
Vk12653 single agent
100 mg/kg
Vehicle-treated Vk12653 tumor-bearing mice in Fig. 1c.No single-agent activity by the reported response criterion.[2]
Vk12598 single agent
Model: Transplantable Vk12598 myeloma in C57BL/6J mice
Reported limits: Caption supplies dose; general methods permit 50 or 100 mg/kg. Exact cohort n not stated in the selected caption.
Vk12653 single agent
Model: Transplantable Vk12653 multidrug-refractory myeloma in C57BL/6J mice
Reported limits: Exact cohort n and cohort-specific enrollment threshold not resolved.
Methods and source locations

Compound reported in the paper: LCL161; Compound label in the paper: LCL161

Applies at the named-compound level; the study did not test an Adooq lot.

Fig. 1b/c and caption; Results, LCL161 exhibits potent preclinical anti-myeloma activity; Online Methods, Cell lines and reagents, Mice, In vivo drug administration

Serum monoclonal M-spike response: Serum protein electrophoresis; gamma/albumin ratio normalized within each mouse to day 0. Each dot is one mouse and horizontal lines are medians. No exact response rate or median digitized. — Fig. 1b/c and caption; Results, LCL161 exhibits potent preclinical anti-myeloma activity; Online Methods, In vivo drug administration

Vk12598 single agent · Fig. 1b and caption; Online Methods, Mice and In vivo drug administration

Vk12653 single agent · Fig. 1c and caption; Online Methods, Mice and In vivo drug administration

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 1005342-46-0
Applications Antagonist of IAPs inhibitor
Formula C26H33FN4O3S
Molecular Weight 500.2
SMILES
C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (171.78 mM)
Water Insoluble
Ethanol Warmed: 17 mg/mL (33.95 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LCL-161 Research References

  1. [1] Wang Y, Liu Z, Si Q, et al. Complex IIa formation and ABC transporters determine sensitivity of OSCC to Smac mimetics. Cell death & disease (2024). PMID: 39578442 DOI: 10.1038/s41419-024-07253-w Source material
  2. [2] Chesi M, Mirza NN, Garbitt VM, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature medicine (2016). PMID: 27841872 DOI: 10.1038/nm.4229 Source material

Publications

10 publications citing this product

  1. Da-Hye Jeong, .et al. , Adv Sci (Weinh), 2025, Apr;12(13):e2412393 PMID: 39921454
  2. Oliver H, .et al. , J Med Chem, 2023, 66, 16, 11216-11236 PMID: 37535857
  3. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  4. Han-Hee Park, .et al. , Mol Cancer, 2021, Aug 21;20(1):107 PMID: 34419074
  5. Se-Yeon Park, .et al. , Cell Death & Disease, 2020, 11:744 PMID: 32917855
  6. J Chen, .et al. , JBC, 2019, June PMID: 31217278
  7. Choi SW, .et al. , Mol Cell, 2018, Jun 7;70(5):920-935.e7 PMID: 29883609
  8. Han-Hee Park, .et al. , Exp Mol Med, 2018, Sep; 50(9): 125 PMID: 30237400
  9. Gi-Bang Koo, .et al. , Cell Res, 2015, Jun; 25(6): 707-725 PMID: 25952668
  10. Kim SK, .et al. , J Invest Dermatol, 2015, Aug;135(8):2021-2030 PMID: 25748555

Added to your cart

View Cart Checkout
Loading...